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Psoriasis is a common inflammatory skin disease with key immunological and genetic components. Recruitment
of leukocytes into the skin is a central step in its pathogenesis, mediated by cytokines. Among the cytokines
expressed in psoriatic lesions, C-C chemokine ligand 4 (CCL4) and C-C chemokine ligand 4-like (CCL4L)
chemokines appear to be pivotal elements for the skin recruitment of proinflammatory cells. The aim of this
study is to evaluate the relationship between CCL4L polymorphisms (including single-nucleotide polymorph-
isms (SNPs) and copy number variation (CNV)) and the course and prognosis of psoriasis. We analyzed the CNV
and the rs4796195 SNP in 211 psoriatic patients and 234 controls; sera from both populations were also
quantified for CCL4/CCL4L protein. Our results showed that a high CNV (X3 copies) is associated with psoriasis
severity, whereas moderate disease correlated with a lower CNV (p2 copies); specifically, the CCL4L1 allele
frequency is higher in severe psoriasis, whereas CCL4L2 is more frequent in patients with a milder disease.
In addition, we found a positive correlation between the CNV and sera protein levels. Our results suggest that
CCL4L genotyping could not only allow a better understanding of the psoriatic pathogenesis but could also be
used as a prognostic tool, even helping to modulate the efficacy of treatments.
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INTRODUCTION
Psoriasis, one of the most common chronic inflammatory skin
disorders, is an immunological disease with a multifactor
etiology involving environmental and genetic factors. It is
characterized by hyperproliferation of keratinocytes with a
prominent cutaneous inflammatory infiltrate predominantly
composed of T helper type-1 and type-17 cells, as well as
neutrophils, macrophages and dendritic cells (Lowes et al.,
2008). An early and relevant step in the psoriatic lesion
development is T-cells trafficking from blood to affected skin.
Key factors in this migration are the chemokines and their
receptors (Nickoloff et al., 2007; Lonsdorf et al., 2009). These
cytokines are involved in regulating leukocyte chemoattrac-
tion, polarization and differentiation of T cells (Luther and
Cyster, 2001). Experimental evidence suggests that T-cell
mediated mechanisms have a primary role in psoriasis
(Krueger and Bowcock, 2005). It is known that activated T
helper type-1 and/or T helper type-17 cells stimulate
keratinocytes to produce cytokines, which further amplify
the inflammatory response at the local level (Schon and
Ruzicka, 2001), and various studies have documented strong
chemokine expression in psoriatic lesions (Pastore et al., 2004;
Nickoloff et al., 2007). The genetic predisposition may include
an altered control of inflammatory gene expression in the skin
(Cargill et al., 2007; Carvalho et al., 2010; Gudjonsson et al.,
2010) involving cytokines and chemokines that would
promote the hyperproliferative response and the vicious cycle
that seems to be associated with psoriasis (Nestle et al., 2009).
The C-C chemokine ligand 4-like (CCL4L) is a non-allelic
copy of C-C chemokine ligand 4 (CCL4) and its protein differs
only in a single amino acid (Modi et al., 2001). CCL4L is
present in copy number variation (CNV) among individuals
(Townson et al., 2002). The CNV is a rich source of genetic
variability (Redon et al., 2006) and it has been reported that
several CNV contribute to autoimmune and inflammatory
disorders susceptibility (Schaschl et al., 2009) by influencing
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the transcription or translation of involved genes (Willcocks
et al., 2008; Carvalho et al., 2010). Some CNVs have also
been associated with psoriasis (Hollox et al., 2008; de Cid
et al., 2009; Huffmeier et al., 2010).
Focusing on the CCL4L gene (also named SCYAAL),
including CNV analysis, we have also genotyped the
rs4796195 single-nucleotide polymorphism (SNP), a poly-
morphism that defines two allelic variants: CCL4L1 (the
original form also called L1) and CCL4L2 (the minor allele
named L2, the major product of which differs in five amino
acids from wild-type protein (Colobran et al., 2005)). Because
of the fact that CCL4/CCL4L chemokines are expressed in
psoriatic lesions (Nomura et al., 2003) and are reported to
stimulate traffic of T helper type-1 cell, regulatory T cells,
monocytes and dendritic cells, the study aim was to evaluate
the influence of CCL4L polymorphisms on the susceptibility
and clinical aspects of psoriasis, evaluating also a possible
correlation between these traits and the protein expression.
RESULTS
Patient population
Mean age of psoriatic patients was 48.5±15.8 years at study
visit. Clinical parameters and systemic treatments are
summarized in Table 1. These clinical manifestations were
considered as the main study variables, although not all
clinical traits were reported in the analysis due to the lack of
significance. The cases were grouped in different cohorts
according to these parameters.
Copy number variation of CCL4L
A total of 211 psoriatic patients and 234 healthy donors were
evaluated.
The CCL4L copies mean was 1.79 in cases and 1.82 in
controls. The distribution of CCL4L copies in both popula-
tions was not statistically different among subjects (Supple-
mentary Table S1 online), consistent with our previous report
(Colobran et al., 2008). Taking ‘‘2’’ as the CCL4L CNV
median value in Caucasian population, cases and controls
were subclassified as follows: (I) absence of the gene or 1
copy, (II) 2 copies, and (III) 3 or more copies. No differences
in CNV were detected between controls and patients
(Supplementary Table S1 online).
Second, we evaluated the relationship between the CNV
and clinical parameters of psoriasis (Figure 1 shows the most
interesting results). Some clinical traits were nominally
associated with higher CCL4L CNV: an early onset, a higher
Psoriasis Area and Severity Index (PASI), a more severe
history of disease (defined by a body surface area (BSA) of
X25% at any moment of the disease) and receiving systemic
treatment; however, none of these associations remained
significant after correction for multiple testing (Figure 1a). The
comparison between CNV means and the clinic pointed in
the same direction (Figure 1b).
To assess the CCL4L1 and CCL4L2 biological role, we also
analyzed the CNV distribution for each allele with respect
to the clinical parameter, being results: a higher number
and mean of L2 copies is significantly associated with a
more stable disease including periods without cutaneous
Table 1. Demographic data, clinical manifestations,
and systemic treatment of psoriatic patients
Variable Frequency (%)
Sex (n=211)
Male 119 (56.40)
Female 92 (43.60)
Family history (n=209)
No 114 (54.55)
Yes 95 (45.45)
Degree relatives (n=95)
First-degree 67 (70.53)
Other relatives 28 (29.47)
Age at the onset (n=208)
After 30 years 88 (42.31)
Before 30 years 120 (57.69)
Disease evolution (n=207)
Intermittent 43 (20.77)
Persistent 164 (79.23)
Psoriatic arthritis (n=209)
No 178 (85.17)
Yes 31 (14.83)
PASI score1 (n=200)
Low 61 (30.5)
Moderate-high 139 (69.5)
BSA score2 (n=200)
o25% 126 (63)
425% 74 (37)
Systemic treatment3 (n=208)
No 117 (56.25)
Yes 91 (43.75)
Autoimmune diseases4 (n=202)
No 192 (95.05)
Yes 10 (4.95)
Chronic infections5 (n=200)
No 193 (96.50)
Yes 7 (3.50)
1Psoriasis Area and Severity Index (PASI) was considered as low level
when the score was o3, moderate and high at 43 PASI score.
2Body Surface Area (BSA) was scored taking into account whether the
affected extension of skin surface was below or over 25%.
3Phototherapy (UVA, UVB, psoralen plus UVA), biological agents
(cyclosporine, methotrexate, efalizumab, infliximab, etarnecept, adali-
mumab), retinoids, and corticosteroids.
4Diabetes mellitus type I.
5Hepatitis C virus and one subject with HIV infection.
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manifestations (intermittent course; corrected P-values¼
0.0474, 0.0369, Figure 2a and c), while a persistent course is
more prevalent in patients lacking L2 (Figure 2a). A trend for
CCL4L1 CNV distribution among patients who had or had not
received treatment was found without statistic significance
(Figure 2b); similarly, who received treatment have a higher L1
mean: uncorrected P-value (uP )¼ 0.0259 (Figure 2c).
Association of L1/L2 SNP with clinical manifestations
Genotype and allele frequencies were similar in cases and
controls (Supplementary Table S2 online). However, some
differences were found when the same genotype and allele
frequencies were analyzed with respect to different clinical
variables (Figure 3). Individuals L2-homozygous suffered
more intermittent than persistent disease, had a low PASI
and BSA scores, and had no concomitant autoimmune
disease. Conversely, a persistent course without other
autoimmune diseases was more frequent in L1-homozygous,
while the lack of the gene showed a higher intermittent
disease frequency, higher BSA, and suffering concomitant
autoimmune disease. More clinical analyses are shown in the
Supplementary Figure S1 online.
HLA-Cw*0602 analysis showed a higher presence in
patients (allele frequency was 25.83%) than in controls
(7.16%), as expected by previous reports (Nair et al., 2006).
However, the HLA-C distribution was equivalent among the
different patient cohorts (Supplementary Table S6 online),
indicating that the differences between groups attributed to
CCL4L variability are not related and not conditioned by
HLA-C*0602.
Combined role of the CCL4L CNV and the L1/L2 SNP
In a previous report we demonstrated (Colobran et al., 2008)
that the L2 allele positively correlates with CCL4L CNV in
human genome. This association was also detected in donors
and patients in our present study; while the correlation of
CNV distribution with the different genotypes was significant
(Po0.0001), these distributions were similar between cases
and controls (Supplementary Figure S2 online).
To evaluate the combined role of CCL4L CNV and each
allele variant (L1 and L2), we used two different approaches.
(i) The first one included the patients classification in two
groups according to their genotype: L1-homozygous and
individuals carrying L2 (at least one copy, regardless of the L1
presence or absence; Supplementary Table S3 online).
Results showed that L1-typed patients with an early onset
had a higher CCL4L copies mean (1.79 vs. 1.56 in late onset,
uP¼0.041). Subjects with L2 and moderate-high PASI
showed a greater copies mean (2.27 vs. 1.85 in low PASI,
uP¼0.010), as was for the BSA (2.43 vs. 1.95, uP¼0.007), for
those undergoing systemic therapy (2.41 vs. 1.95, uP¼0.008)
and those suffering from concomitant autoimmune disease
(2.80 vs. 2.11, uP¼0.043). In any case, the correction for
multiple testing did not remain significant. (ii) For the second
approach, individuals were classified according to their
genomic ratio of L1 and L2 copies. Their distribution was
similar among cases and controls (Supplementary Figure S3a
online), but when patients were divided according to clinical,
results showed than in the gene absence, most individuals (a)
had first-degree relatives, (b) presented an intermittent
course, (c) a higher BSA, (d) received systemic therapy, and
Onset Disease course PASI score BSA
CCL4L copies
Treated Autoimmunediseases Medical history
P=0.2782 (0.7213)P=0.0811 (0.2453)P=0.0087 (0.0807)P=0.0198 (0.1197)P=0.0424 (0.1923)P=0.0541(0.2305)P=0.0089 (0.0807)
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Figure 1. Association of CCL4L copy number with clinical manifestations of psoriasis. (a) Distribution of CCL4L copy number variation (CNV) in psoriatic
patients grouped according to the number of copies per genome (0–1, 2, and 3–4) and their most relevant evaluated clinical parameters. The correlation between
the distribution of CCL4L copy number and the different clinical manifestations was analyzed by w2or Fisher’s test, when appropriate. (b) Mean and ±SD of
CCL4L CNV according to clinical parameters in these subsets of patients, evaluated by the Kruskal–Wallis test. Nominal and corrected P-values in parentheses
are reported. BSA, body surface area; CCL4L, C-C chemokine ligand 4-like; PASI, Psoriasis Area and Severity Index.
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(e) suffered concomitant autoimmune disease. The majority
of patients where the L1 variant was the most abundant (a)
had persistent psoriasis, (b) showed higher BSA, (c) increased
PASI, (d) required treatment, and (e) developed psoriatic
arthritis. Inversely, when the L2 was prevalent, most of the
cases (a) had an intermittent course, (b) showed lower BSA,
(c) lower PASI, and (d) did not need systemic treatment
(Supplementary Figure S3b online).
Serum levels correlate with CNV
To confirm defined correlations based on genotyping, we
evaluated protein expression measuring the CCL4/CCL4L
concentration in sera of patients and controls. In fact, only
scarce evidence exists (Melzer et al., 2008) demonstrating a
correlation between protein expression and CNV, where the
rs4796217 SNP of CCL4L was associated with protein levels,
although authors assume that probably this SNP position and
its protein association may be related to CNV in the gene.
Our evaluation provides an additional element of interest
because protein measurements were performed simulta-
neously with the CNV. We found an association between
the chemokine levels and the CCL4L or CCL4L1 CNV, both in
donors and patients (Figure 4a and b, respectively). Although
the protein levels were equivalent in both populations, we
found positive correlations for the CCL4L total number
(Spearman’s r¼0.409, Po0.0001 in controls and r¼0.417,
P¼0.0074 in cases) and for CCL4L1 (Spearman’s r¼0.361,
Po0.0001 in controls and r¼0.411, P¼0.0085 in cases).
However, a lack of association between the rs4796217
and protein levels was found in both controls and patients
(Supplementary Figure S4a and b online).
CCL4/CCL4L genotype and protein levels correlate with
psoriasis severity
To study the CCL4L genotyping role in psoriasis, we divided
the patients into three cohorts: mild, moderate, and high
P=0.5952 (0.8928)
I P
80
60
3 3
CCL4L
CNV
%LI
copies
%L2
copies
2 21 10 0
40
20
20
40
60
80
P=0.0158 (0.0474)
0 CCL4LCNV
Not treated Treated
3 32 21 10 0
P=0.9179 (1.0000)
P=0.0565 (0.1695)
80
60
40
20
20
40
60
80
0
P=0.7914
(1.0000)2.0
1.5
1.0
0.5
0.0
I P I P N
o
Ye
s
N
o
Ye
s
L1 L1L2 L2
Systemic treatmentDisease course
L1
 o
r L
2 
co
py
 m
ea
n
P=0.0123
(0.0369)
P=0.0259
(0.0885)
P=6285
(0.9427)
Figure 2. Role of L1 and L2 allele copies in the evolution of disease and systemic treatment on the psoriasis. (a, b) Distribution (in percentage) of the
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disease severity. Interestingly, we found a statistically signi-
ficant CNV distribution among these cohorts (Figure 5a,
corrected P-value¼0.042). Specifically, we obtained a
positive correlation between high psoriasis severity and the
possession of more than two CCL4L copies. On the other
hand, when we analyzed the L1/L2 genotype, we observed
an elevated proportion of L2-homozygous in the mild severity
cohort (with no individuals for this genotype in the moderate
or high severity). Peculiarly, the most cases lacking the gene
were in the high severity cohort (Figure 5b).
CCL4/CCL4L protein expression was also positively
correlated with the clinical severity (Spearman’s r¼0.347,
P¼0.028; Figure 5c), supporting our genotyping results.
DISCUSSION
CCL4L is affected by CNV and some CNVs are clearly
associated with inflammatory and infectious diseases
(Colobran et al., 2009, 2010; Shostakovich-Koretskaya
et al., 2009). Owing to this evidence, we were interested
in investigating whether CCL4L polymorphisms may have
a role in the psoriasis prognosis.
The first point to highlight is that CCL4L polymorphisms do
not appear to be involved in psoriasis susceptibility (no
differences were observed between patients and controls).
However, in our study, we have shown that CCL4L
polymorphisms and their protein levels correlate with the
psoriasis course. A role can be deduced when considering the
disease evolution: patients with high CCL4L CNV had an
elevated risk of developing severe psoriasis, while milder
disease was more frequent in those who had a lower CNV. In
fact, our data about the CCL4L CNV and the L1/L2 SNP could
explain some of the clinical differences observed in the
disease, supporting the generally accepted evidence of
the relationship between clinical phenotype and genomic
information.
The positive correlation between the CNV and protein
expression reinforces these observations, and points that
CCL4L CNV has a gene dosage effect. Although in a previous
report (Melzer et al., 2008) the rs4796217 was associated
with chemokine levels, our study demonstrates that it is the
CCL4L CNV and not this SNP which alters the expression.
This phenomenon could explain the variability in phenotype:
higher protein levels may be related to more severe psoriasis.
It could be speculated that an enhanced capacity of T helper
type-1 cell, T helper type-17 cell, monocytes and dendritic
cells attraction, encouraging infiltration into skin, could lie at
the basis of disease severity (Krueger et al., 1995). This is also
supported because the infiltrating cells express C-C chemo-
kine receptor 5, the ligand for CCL4, which has also been
involved in psoriasis (Lowes et al., 2007; Kagami et al., 2010)
and reported as predominant in skin lesions (Steinman, 2007;
Lowes et al., 2008).
Not only the CNV evaluation but also the L1/L2 alleles
analysis helped to identify the differences in the psoriatic
course. L1 could be associated with a more severe disease: an
increased CCL4L1 number correlated with the treatment
requirement. Also, those L1-homozygous patients presented a
higher persistent disease frequency and an earlier debut. In the
same way, a higher L1/L2 ratio showed a tendency for higher
BSA and PASI scores. Results were consistent with previous
reports showing similar in vitro functions for CCL4 and CCL4L1
(Howard et al., 2004). In contrast, L2 presence seems likely to
be associated with a better prognosis: L2-homozygous had a
higher mild disease frequency and lower PASI and BSA. The L2
variant may have lower activity as suggested by bioinformatics
data, due to the five amino-acid lack in the protein (Colobran
Disease evolution
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Figure 3. Genotype and allele frequencies of rs4796195 single-nucleotide polymorphism according to relevant clinical manifestations in patients with psoriasis.
(a) L1/L2 genotype frequencies. Individuals lacking the CCL4L gene are included (null genotype). (b) L1/L2 allele frequencies. Data were analyzed by Fisher’s test.
Nominal and corrected P-values (in parentheses) are shown. BSA, body surface area; CCL4L, C-C chemokine ligand 4-like; PASI, Psoriasis Area and Severity Index.
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et al., 2005) located in the glycosaminoglycan-binding region.
The chemokines immobilization on the cell by glycosamino-
glycans interaction may be a main step in determining
chemokine activity (Mulloy and Rider, 2006) and chemoattrac-
tion (Olson and Ley, 2002). Although it has not been
demonstrated yet, the L2 would have lower affinity for
glycosaminoglycans, resulting in a decrease of chemokine
concentration and subsequent decrease in leukocyte infiltra-
tion, determining the ‘‘mild phenotype’’ in psoriasis.
Surprisingly, most of patients lacking the gene was in the
severe disease cohort. CCL4 is commonly regarded as a
proinflammatory factor, but evidence exists with an addi-
tional, regulatory role (Menten et al., 2002) that would
explain why the CCL4L lack results as phenotype: high PASI,
greater skin lesions and an intermittent course. Furthermore,
it has been demonstrated that CCL4 attracts FoxP3þTreg
and these cells are increased in patients, correlating with
disease (Yan et al., 2010; Zhang et al., 2010). In conse-
quence, the CCL4L absence could cause a decrease
in T-regulatory cells and therefore a deficient regulation of
the inflammatory process.
Although genome-wide scans reveal an association
between several genetic loci and provide new insights into
disease mechanisms (Elder et al., 2009; Nair et al., 2009),
there is no direct evidence about the CCL4 role in the
psoriasis pathogenesis, probably because these studies are
not specific enough, nor allow an accurate CNV assessment.
Further research is needed to elucidate the relationships
between psoriasis-susceptibility genes, the transcripts they
express and those cells involved in the initiation and/or
perpetuation of psoriasis.
As mentioned, L1/L2 genotyping combined with CNV
analysis can help to psoriatic prognosis; thus, a more rapid
and aggressive treatment could be undertaken in those
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patients with a higher CCL4L1 CNV, particularly when high
chemokine levels are detected. But the statistical significance
of the most associations in this work is modest and will
require replication in larger samples.
A greater understanding of genetic defects associated with
psoriasis should allow for the development of novel therapies
and the ‘‘tailoring’’ of existing therapies to the genotype of a
patient. And, as with other biological therapies (Puig et al.,
2009), it is reasonable to test approaches to specifically
interfere with leukocyte recruitment as a psoriasis treatment.
Therefore, the CCL4L variants modulation must be consid-
ered as a probably new target for future therapies and to
better understand the psoriasis pathogenesis.
MATERIALS AND METHODS
Subjects
A total of 211 psoriatic patients diagnosed by the dermatologist of
the Hospital Universitari Germans Trias i Pujol (HUGTiP; Barcelona,
Spain) were included in this study. One of the main issues was to
characterize the clinical psoriasis severity. The PASI evaluation is
well recognized as a tool to identify psoriasis severity and was
registered for all patients at the recruitment moment. As most of the
patients remained under treatment at the study visit, to evaluate the
disease severity, additional factors were considered: including the
highest BSA involved at any disease moment, a persistent psoriasis
including flares or a more stable disease including periods without
cutaneous manifestations (intermittent clinical course), the need for
systemic treatment to achieve disease control, and some prognostic
features as the age of onset and relatives with psoriasis (Ferra´ndiz
et al., 2002). Finally, we registered the psoriatic arthritis history,
diagnosed by a rheumatologist independently of cutaneous involve-
ment, as a different subset marker of psoriatic patients. All patients
were scored according to epidemiological, clinical parameters and
medication that they received (demographic data and main clinical
features are summarized in Table 1). The study also includes 234
control samples from the same hospital.
To evaluate psoriasis severity, we divided the patients into three
cohorts (mild, moderate, and high, referring to the disease severity)
according to the clinical manifestations number displayed by
patients. Parameters taken into account were six: (a) an early onset,
(b) persistent disease, (c) moderate/high PASI, (d) BSA 425%, (e)
receiving systemic treatment, and (f) suffering from psoriatic
arthritis. Therefore, the ‘‘mild’’ severity group includes patients with
0, 1, or 2 clinical manifestations, the ‘‘moderate’’ group refers to the
subjects with 3 or 4 variables, and the ‘‘high’’ severity cohort
includes patients who present the highest number of clinical
parameters, 5 or 6.
The study was approved by the Medical Ethics Committee of
HUGTiP, and written consent was obtained from all participants;
this work was conducted according to the Declaration of Helsinki
principles.
CCL4L copy number determination
We analyzed the CCL4L CNV as previously described (Colobran
et al., 2008). Briefly, this assay is performed by using quantitative
reverse transcription–PCR in an ABI-PRISM7900HT Fast Real-Time
PCR Instrument (Applied Biosystems, Foster City, CA; primers and
probe in Supplementary Table S5 online) to allow specific CCL4L
amplification and detection (see Supplementary Figure S5 online). In
the same reaction, we included a reference gene: RNaseP (TaqMan
RNaseP Control; Applied Biosystems), according to the manufac-
turer’s recommendation. All samples were analyzed in duplicate and
equally treated. Average CNV±SD was assigned to each sample,
but when SD was 410% of the average, the values were excluded
and the CNV evaluation was repeated. The quantification’s details
are in Supplementary Materials and Methods online and results for
the unrounded CNV in the Supplementary Figure S6 online.
Genotyping
Genotyping for CCL4L1/CCL4L2 variants defined by rs4796195 was
performed (Colobran et al., 2008) by reverse transcription–PCR in a
LightCycler480 Instrument (Roche, Mannheim, Germany; primers
and probes in Supplementary Table S5 and Figure S5 online) using
the methods previously described. The rs4796217 genotyping was
analyzed by PCR-restriction fragment length polymorphism (PCR
primers in Supplementary Table S5 online and enzymatic
digestion with MnlI (New England BioLabs, Hitchin, UK)). The
HLA-C genotyping was performed by Luminex PCR-SSO with the
Lifecodes HLA-C Typing kit (Gen-Probe, San Diego, CA); we
analyzed the HLA-Cw0602 allele frequencies for all psoriatic
patients as the main risk factor for psoriasis. We analyzed the
HLA-C genotyping from 1,600 blood donors from our data base
as control population.
Numerical allelic discrimination in heterozygous subjects
We estimated the exact copy number of each allele in heterozygous
individuals for rs4796195 SNP as previously described (Colobran
et al., 2008). This analysis was applied when more than two CCL4L
copies were detected simultaneously with the presence of two allelic
variants (CCL4L1 and CCL4L2) in the same sample.
To assess the biological role of each variant, the L1 and L2 genomic
ratio was calculated for each individual as follows: in the gene
absence, the ratio is 0; if the same number of copies for each allele is
present, the ratio is equivalent to 1; when the L1 copies are higher than
L2, the ratio is 41; and if they are lower, it corresponds to o1 ratio.
Chemokine levels in serum samples
CCL4/CCL4L levels in serum samples from 40 patients and 187
donors (47 donors were rejected after showing positivity for a
screening panel of auto-antibodies; see Supplementary Table S4
online) were determined by using DuoSet-ELISA Development kit, a
sandwich ELISA (R&D systems, Minneapolis, MN) following the
manufacturer’s recommendations. The ability to recognize both
forms (CCL4 and CCL4L) was defined by using recombinant proteins
produced in transfected CHO cells. All samples were analyzed
in duplicate, and when the SD value was higher than 10% or
the quantification was not acceptable, we repeated the assay,
pre-diluting the sample if necessary.
Statistics
To test the association between copy number means and clinical
parameters we used the Kruskal–Wallis test. Differences in CNV
distribution, genotypes, or allele frequencies among the clinical cohorts
were assessed by the w2 or Fisher’s exact test, when appropriate.
The association between chemokine levels and CNV was tested by
the Spearman’s rank correlation coefficient. Additionally, post hoc
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assessment was performed by Dunn’s test and multiple testing
correction by the Benjamini–Hochberg–Yekutieli procedure. Statistical
analysis was performed using Graph-Pad Prism v.5 (Graph-Pad
Software, San Diego, CA) and R package version 2.10. Significance
was evaluated by corrected and uncorrected P-values.
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